New Enterprise Associates

Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

858 Therapeutics is a biotechnology company dedicated to discovering small molecule therapeutics aimed at treating cancers, particularly those resistant to existing therapies. The company employs innovative strategies centered on synthetic lethality, innate immunity, and RNA modulation to develop its drug pipeline. Its lead program focuses on a PARG inhibitor, which is currently undergoing early clinical development. By leveraging its platform to evaluate the effects of RNA modifying proteins on disease biology, 858 Therapeutics aims to generate effective treatments for challenging oncological targets.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

PayZen is a healthcare fintech startup founded in 2019 in San Francisco by Ariel Rosenthal, Itzik Cohen, and Tobias Mezger. The company addresses the challenge of patient payment responsibilities by providing a platform that allows patients to pay their out-of-pocket medical bills over time, enhancing convenience and transparency. PayZen's technology utilizes artificial intelligence to create tailored payment plans that cater to individual financial situations, thereby improving affordability for patients. This approach not only facilitates timely payments but also helps medical providers optimize cash flow and minimize the costs associated with collecting outstanding invoices. By focusing on patient financing solutions, PayZen enables healthcare providers to concentrate on delivering medical care rather than managing financial transactions.

In-House Health is an AI-powered technical platform for modern nursing teams.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Nexo Therapeutics is a biotechnology company focused on developing small-molecule therapies for cancer patients who have few effective treatment options. The company utilizes a specialized platform that integrates covalent ligand discovery with chemical biology to create innovative oncology drugs aimed at challenging targets that have been difficult to address in the past. By advancing its pipeline of novel therapies, Nexo Therapeutics seeks to provide new avenues for treatment, ultimately enhancing the care available to individuals battling cancer and other related diseases.

Spyglass Pharma specializes in developing innovative treatments for chronic ophthalmic diseases, leveraging advanced technology to enhance patient care and vision. The company focuses on creating ophthalmic devices and a drug delivery platform that addresses unmet needs in areas such as cataracts and lens replacement surgeries. Its delivery system is designed to be implanted alongside intraocular lenses during standard cataract procedures, allowing surgeons to administer multi-year therapies for chronic conditions. This approach aims to improve the accessibility and affordability of quality eye treatments for patients, ensuring better outcomes in ophthalmic care.

Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.

Minerva Surgical Inc. is a medical technology company based in Redwood City, California, specializing in women's healthcare. Founded in 2008, the company develops, manufactures, and commercializes minimally invasive solutions aimed at addressing the unique uterine health needs of women. Its flagship product, The Minerva Endometrial Ablation System, provides a treatment option for abnormal uterine bleeding, a common issue among women. Minerva Surgical offers a range of alternatives to hysterectomy, designed to tackle the leading causes of abnormal uterine bleeding while preserving the uterus and minimizing the drawbacks associated with traditional treatment methods. The company's solutions are suitable for various medical settings, reflecting its commitment to improving women's health outcomes.

Launchpad Therapeutics operates as an antibody-focused precision oncology company.

Elion operates a digital health software marketplace that connects healthcare builders with a variety of software and service vendors through its online platform. The company provides comprehensive vendor listings, detailed product evaluations, and educational resources, allowing healthcare providers to research, compare, and select technology solutions tailored to improve their operations and enhance patient care. By facilitating informed technology decisions, Elion aims to support both startups and established organizations in delivering better healthcare outcomes.

Moximed, Inc. is a medical technology company based in Hayward, California, focused on developing innovative solutions for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain for individuals suffering from medial compartment knee osteoarthritis. This system operates similarly to a shock absorber, providing dynamic load reduction to minimize joint pain and enhance mobility. Moximed also features the MISHA Knee System, which offers an outpatient treatment option for patients who have not found relief through other therapies and are not suitable candidates for knee replacement surgery. By addressing the specific needs of osteoarthritis patients, Moximed aims to improve their quality of life while potentially delaying the need for more invasive surgical interventions. Founded in 2006, the company serves patients and medical professionals worldwide.

Everside Health is a direct primary care provider based in Denver, Colorado, founded in 2010. The company offers convenient on-site, near-site, and virtual care services to patients across the nation. Everside Health focuses on a data-driven, patient-centered healthcare delivery model that enhances engagement between patients and physicians. Its services include biometric screenings, health risk assessments, lifestyle coaching, and acute care. By aligning incentives among patients, physicians, and benefit providers, Everside aims to improve overall health outcomes while reducing the total cost of care.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Evernow is a provider of women's health care services focused on supporting women before, during, and after menopause. The company offers an online teleconsultation platform that connects users with specialized doctors and provides access to science-backed information and treatments. Through this platform, Evernow facilitates conversations about effective care for managing changing hormones, empowering women to lead longer and healthier lives.

Uniphore Software Systems Private Limited specializes in developing multilingual speech recognition software solutions aimed at enhancing customer interactions through speech analytics, virtual assistance, and voice biometrics. The company provides an integrated suite of software products that includes conversational analytics, a conversational assistant, and conversational security, all designed to improve customer service. Its offerings, available as software as a service (SaaS), include tools such as auMina for customer service transformation, auMina QSense for performance analytics, auMina Real-Intent for real-time conversational insights, akeira as an AI-enabled assistant for customer engagement, and amVoice for conversational security to combat fraud. Uniphore serves a diverse range of sectors, including banking, insurance, retail, healthcare, and government. Founded in 2008 and headquartered in Chennai, India, the company also has offices in Manila, Dubai, Palo Alto, and Singapore.

Nitra is a financial technology company focused on enhancing the healthcare industry through efficient and transparent solutions. The company offers a platform that provides machine learning-powered financial software, including credit cards, loans, accounts, payments, and expense management tailored for medical professionals. Nitra's tools help healthcare providers streamline their spending and manage payments in one centralized location, offering a clear overview of daily expenses. The Nitra Visa Business Card rewards users with benefits for every transaction and provides access to discounts through a network of partners. By simplifying accounting and receipt reconciliation, Nitra aims to support healthcare providers in balancing patient care with efficient practice management, delivering modern technology and dedicated support to the sector.

Waymark is a company focused on enhancing access to and the quality of healthcare for individuals receiving Medicaid. It offers community-based healthcare services designed to improve health outcomes for Medicaid beneficiaries. The company collaborates with primary care providers and equips community care teams with essential resources, including health plans, insulin education, and training. Through these efforts, Waymark aims to support patients in effectively managing their health and navigating the healthcare system.

Belong Health works with local health plans to provide regionally informed, humanistic care to a rapidly expanding community of need.

Simple psychology belongs to Beijing Zhujian Technology Co., Ltd. Simple psychology focuses on providing high-quality psychological services.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Recludix Pharma is a biotechnology company focused on drug discovery, specifically targeting the development of potent and selective inhibitors for challenging protein targets associated with cancer and autoimmune diseases. The company utilizes a unique platform that combines custom-generated DNA-encoded libraries with massively parallel structure-activity relationship determination and proprietary screening tools. This integrated approach aims to enhance the identification and development of novel small molecule medicines, enabling healthcare professionals to create precision therapies that effectively address specific protein targets in these complex diseases.

858 Therapeutics is a biotechnology company dedicated to discovering small molecule therapeutics aimed at treating cancers, particularly those resistant to existing therapies. The company employs innovative strategies centered on synthetic lethality, innate immunity, and RNA modulation to develop its drug pipeline. Its lead program focuses on a PARG inhibitor, which is currently undergoing early clinical development. By leveraging its platform to evaluate the effects of RNA modifying proteins on disease biology, 858 Therapeutics aims to generate effective treatments for challenging oncological targets.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Allay Therapeutics is focused on developing innovative pain management solutions aimed at improving post-surgical recovery for patients. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutic products. These products are designed to deliver targeted pain relief at the surgical site over extended periods, significantly longer than conventional pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical trial for total knee arthroplasty surgeries. With a team of experienced entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics is dedicated to transforming the approach to pain management and addressing the limitations associated with opioid use.

Woebot Health is a digital mental healthcare provider that focuses on delivering personalized support through an innovative platform. This platform integrates advanced artificial intelligence and natural language processing with established therapeutic techniques to create engaging mental health tools. At the core of its offering is Woebot, a relational agent designed to provide continuous, empathic, and personalized care. By leveraging these technologies, Woebot Health enables individuals and businesses to access effective mental health support conveniently and seamlessly, fitting into everyday life and promoting overall well-being.

Spiras Health operates a healthcare organization focused on delivering specialized treatment to patients with complex chronic conditions in their homes. The company employs a multidisciplinary team of clinicians to provide home-based clinical services, which are enhanced by telehealth, two-way digital communications, and remote patient monitoring. This approach aims to improve patients' quality of life while minimizing the costs associated with unnecessary hospitalizations. Spiras Health is dedicated to offering compassionate and specialized care tailored to the needs of each patient, ensuring they receive the support necessary to manage their health effectively in a familiar environment.

Stablix Therapeutics is a biotechnology company specializing in Targeted Protein Stabilization (TPS). The company has developed a platform that produces heterobifunctional small molecules, known as RESTORACS, which selectively recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins. This process enhances the stability and activity of these proteins. Stablix focuses on utilizing its innovative technology to create therapeutic programs aimed at treating rare diseases, cancer, and immunological disorders. By restoring protein function, Stablix aims to provide more effective treatment options for complex medical conditions.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Cleo is a family support system that employers offer working parents, by helping families navigate their journey from fertility, to pregnancy, to parenting of newborns, infants, toddlers, and children to age 5. Employers choose Cleo as a strategic partner to power their culture transformation and see increased employee retention, more diverse and inclusive workplaces, and reduced health claims. Cleo supports parents globally in 50+ countries and works with forward-thinking companies like eBay, LinkedIn, Uber, and Straus Family Creamery and many others. Cleo is headquartered in San Francisco and is backed by Felicis Ventures, Forerunner Ventures, Greylock Partners, and NEA. Learn more at hicleo.com.

Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

Spyglass Ophthalmics develops ophthalmic devices intended to improve vision and eye care of patients. Spyglass' devices address unmet needs in cataract, lens replacement, surgery, and other chronic ophthalmic diseases, enabling patients to get quality eye treatment at an affordable cost.

Resilience is a technology-driven biomanufacturing company focused on enhancing access to complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. The firm aims to transform the production of medicine by providing a comprehensive range of customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals throughout all stages of drug development, from pre-clinical to commercial supply. Resilience is committed to creating a sustainable network of advanced manufacturing solutions that ensure rapid, safe, and scalable production of treatments, thereby enabling partners to concentrate on breakthrough discoveries that improve patient outcomes. The company's innovative approach also strengthens biopharmaceutical supply chains, preparing them for future challenges.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Tempus Labs, Inc. is a technology company based in Chicago, Illinois, that focuses on advancing precision medicine through the application of artificial intelligence in healthcare. Founded in 2015, Tempus has established one of the world's largest libraries of clinical and molecular data, enabling physicians to make real-time, data-driven decisions for personalized patient care. The company offers a range of services, including genomic sequencing, clinical data restructuring, image recognition, and biological modeling. By collecting, cleansing, and analyzing data, Tempus facilitates the discovery, development, and delivery of optimized therapeutic options for patients. Its innovative platform aims to enhance the accuracy and personalization of laboratory tests, ultimately benefiting patients through insights gained from previous cases.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Evenly is a technology platform that specializes in orthodontics, aiming to enhance oral health and wellness through innovative solutions. Founded in 2019 and headquartered in Washington, D.C., the company leverages AI technology and 3D printing to deliver precise orthodontic treatments, including advanced Invisalign options. Its platform allows for remote treatment management, offering patients regular check-ins with orthodontists and clinical experts. By integrating these technologies, Evenly seeks to improve the overall patient experience and accessibility to high-quality orthodontic care across the country.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Tempus Labs, Inc. is a technology company based in Chicago, Illinois, that focuses on advancing precision medicine through the application of artificial intelligence in healthcare. Founded in 2015, Tempus has established one of the world's largest libraries of clinical and molecular data, enabling physicians to make real-time, data-driven decisions for personalized patient care. The company offers a range of services, including genomic sequencing, clinical data restructuring, image recognition, and biological modeling. By collecting, cleansing, and analyzing data, Tempus facilitates the discovery, development, and delivery of optimized therapeutic options for patients. Its innovative platform aims to enhance the accuracy and personalization of laboratory tests, ultimately benefiting patients through insights gained from previous cases.

Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.

Spyglass Ophthalmics develops ophthalmic devices intended to improve vision and eye care of patients. Spyglass' devices address unmet needs in cataract, lens replacement, surgery, and other chronic ophthalmic diseases, enabling patients to get quality eye treatment at an affordable cost.

THE WELL is a membership-based wellness club and spa located in New York City, catering to busy urban professionals. The organization integrates both Western medicine and Eastern healing practices to create a comprehensive health ecosystem. It offers personalized wellness plans developed collaboratively by integrative medicine doctors, health coaches, and skilled practitioners. The focus is on whole-person care, enabling members to take an active role in their health through tailored consultations and customized experiences. By combining modern medical insights with traditional healing wisdom, THE WELL empowers its community to maintain their health and well-being effectively.

Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Strive Health, LLC, founded in 2018 and based in Denver, Colorado, specializes in solutions for chronic kidney disease. The company operates dialysis centers and employs a technology-enhanced clinical model to improve patient outcomes and experiences. Strive Health works collaboratively with innovative payers and providers to transform kidney care by focusing on the entire healthcare journey of chronic kidney disease patients, from primary care engagement to dialysis treatment. The company utilizes predictive analytics and comparative data to identify at-risk patients and aims to reinvent primary care to address kidney disease proactively, reducing the need for inpatient services and promoting home dialysis options. Backed by notable investors, Strive Health is committed to enhancing the management and care of patients with chronic kidney disease.

Cleo is a family support system that employers offer working parents, by helping families navigate their journey from fertility, to pregnancy, to parenting of newborns, infants, toddlers, and children to age 5. Employers choose Cleo as a strategic partner to power their culture transformation and see increased employee retention, more diverse and inclusive workplaces, and reduced health claims. Cleo supports parents globally in 50+ countries and works with forward-thinking companies like eBay, LinkedIn, Uber, and Straus Family Creamery and many others. Cleo is headquartered in San Francisco and is backed by Felicis Ventures, Forerunner Ventures, Greylock Partners, and NEA. Learn more at hicleo.com.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Tiburio Therapeutics, Inc. is a biotechnology company focused on developing and manufacturing medicines for diseases related to the endocrine system. Founded in 2018 and based in Cambridge, Massachusetts, the company is advancing clinical-stage compounds aimed at treating rare neuroendocrine tumors and endocrine diseases. Notably, Tiburio is developing TBR-760, which targets non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule designed to shrink or halt tumor growth. Additionally, Tiburio is working on TBR-065 for other rare endocrine diseases, addressing significant patient needs in these underserved areas.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Lungpacer Medical Inc. is a medical device company specializing in therapeutic solutions aimed at enhancing the treatment of critically ill patients who require mechanical ventilation. Founded in 2009 and headquartered in Vancouver, Canada, with an additional office in Exton, Pennsylvania, the company has developed the Lungpacer DPT System. This diaphragm pacing system utilizes a temporary, minimally invasive, transvascular nerve stimulation technique to activate the diaphragm muscle, preserving its strength and integrity. By addressing the significant health and cost challenges associated with mechanical ventilation in Intensive Care Units, Lungpacer Medical aims to improve patient outcomes and reduce hospital care costs. The technology is designed to restore negative pressure ventilation, offering a more physiological respiratory pattern and mitigating the harmful effects associated with positive pressure ventilation.

Allay Therapeutics is focused on developing innovative pain management solutions aimed at improving post-surgical recovery for patients. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutic products. These products are designed to deliver targeted pain relief at the surgical site over extended periods, significantly longer than conventional pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical trial for total knee arthroplasty surgeries. With a team of experienced entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics is dedicated to transforming the approach to pain management and addressing the limitations associated with opioid use.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates aimed at treating epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, Xenon is developing XEN007, a central nervous system-acting calcium channel modulator, also in Phase I trials. The company leverages insights from genetic research, particularly from families with severe phenotypes, to identify drug targets, which may extend beyond rare genetic disorders. Furthermore, Xenon has established a collaboration with Neurocrine Biosciences to advance the development of innovative epilepsy treatments.

CPS is a hospital solutions provider that specializes in enhancing operations and supporting patient care within healthcare organizations. Previously known as Comprehensive Pharmacy Services, CPS offers a range of services, including inpatient pharmacy management, telepharmacy, consulting, and outpatient pharmacy management. By delivering expert technology solutions and tailored support, CPS assists hospitals and health systems in addressing various challenges while improving financial and clinical performance. The company's focus on empowering healthcare organizations aims to advance the standard of care and enhance patient satisfaction.

NeueHealth Inc is a healthcare company dedicated to providing high-quality, coordinated care to all health consumers, particularly those in aging and underserved populations. The company focuses on making healthcare accessible and affordable through strategic partnerships with providers and payors, aligning their interests to enhance the overall healthcare experience. By leveraging technology and data analytics, NeueHealth offers a suite of services that empower independent providers and medical groups to succeed in performance-based arrangements. This approach not only optimizes clinical outcomes but also aims to drive down costs and reduce systemic waste, ultimately delivering a more personalized and efficient healthcare experience for its members across various insurance markets, including the ACA Marketplace, Medicare, and Medicaid.

Sleep Reset is a personalized sleep program that utilizes a science-backed approach to address insomnia and improve sleep quality. Clinically proven to enhance total sleep time by an average of 85 minutes, the program effectively reduces the time taken to fall asleep and the frequency of nightly awakenings by nearly half. Participants work with a dedicated sleep coach who tailors the program to their specific needs, focusing on the underlying causes of sleep issues. This approach provides a sustainable solution for better sleep without the use of medications or melatonin. Developed in collaboration with sleep experts from esteemed institutions like Stanford and Yale, Sleep Reset has garnered recognition from various prominent publications and has received support from notable Silicon Valley investors. The program offers a comprehensive solution for individuals seeking to alleviate sleep anxiety and improve their overall sleep health.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for serious liver diseases. Founded in 2018 and based in Foster City, California, the company focuses on addressing rare and orphan diseases. Its lead product candidate, maralixibat, is an investigational oral drug currently in Phase 3 clinical trials for treating progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), and biliary atresia. Additionally, Mirum is developing volixibat, aimed at treating intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company’s commitment to innovative therapies positions it as a key player in the biopharmaceutical landscape dedicated to improving the lives of patients with debilitating liver conditions.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases. It develops multiple antibiotic drugs intended to combat antimicrobial resistance. The company's technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases, deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance, enabling medical businesses optimal use of products and critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. It was founded in 2018 and is headquartered in San Diego, California.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Tempus Labs, Inc. is a technology company based in Chicago, Illinois, that focuses on advancing precision medicine through the application of artificial intelligence in healthcare. Founded in 2015, Tempus has established one of the world's largest libraries of clinical and molecular data, enabling physicians to make real-time, data-driven decisions for personalized patient care. The company offers a range of services, including genomic sequencing, clinical data restructuring, image recognition, and biological modeling. By collecting, cleansing, and analyzing data, Tempus facilitates the discovery, development, and delivery of optimized therapeutic options for patients. Its innovative platform aims to enhance the accuracy and personalization of laboratory tests, ultimately benefiting patients through insights gained from previous cases.

Everside Health is a direct primary care provider based in Denver, Colorado, founded in 2010. The company offers convenient on-site, near-site, and virtual care services to patients across the nation. Everside Health focuses on a data-driven, patient-centered healthcare delivery model that enhances engagement between patients and physicians. Its services include biometric screenings, health risk assessments, lifestyle coaching, and acute care. By aligning incentives among patients, physicians, and benefit providers, Everside aims to improve overall health outcomes while reducing the total cost of care.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on addressing significant unmet medical needs by creating distinct therapies that improve clinical care. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing the quality of life for patients, families, and caregivers.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Everside Health is a direct primary care provider based in Denver, Colorado, founded in 2010. The company offers convenient on-site, near-site, and virtual care services to patients across the nation. Everside Health focuses on a data-driven, patient-centered healthcare delivery model that enhances engagement between patients and physicians. Its services include biometric screenings, health risk assessments, lifestyle coaching, and acute care. By aligning incentives among patients, physicians, and benefit providers, Everside aims to improve overall health outcomes while reducing the total cost of care.

CareZone is a healthcare platform that simplifies personal healthcare management and pharmacy delivery services. It offers tools to automate prescription refill reminders, track medical appointments, and manage health information for individuals and families. The platform allows users to coordinate care effectively by providing controlled access for family members and caregivers. By consolidating healthcare tasks into a single interface, CareZone enhances the ability of users to organize their health needs and streamline communication among those involved in their care.

Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them. The company's core technology, the Vesper DUO Venous Stent System, is purpose-built for venous stenting, with an unmatched combination of strength and flexibility designed to meet the multiple anatomical challenges presented by vein mechanics. Vesper Medical is advancing the treatment of deep venous disease by creating a highly differentiated, purpose-built venous stent portfolio that addresses the multiple anatomical challenges presented by the iliac and femoral veins. It also develops minimally- invasive peripheral vascular products. Vesper Medical was founded in 2016 and is headquartered in Wayne, PA, USA.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, focused on developing minimally invasive products for peripheral vascular procedures. Established in 2011, the company is known for its Tack Endovascular System, which enhances the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). This innovative technology aims to improve clinical outcomes and quality of life for patients suffering from vascular diseases, offering physicians a new and effective treatment option. Intact Vascular is dedicated to creating safe, efficacious, and user-friendly medical devices for healthcare providers and their patients.

Welltok is a data-driven enterprise SaaS company based in Denver, Colorado, focused on enhancing consumer engagement in health and wellness. Founded in 2009, Welltok's leading consumer activation platform enables health plans, employers, providers, and public entities to connect individuals with personalized health improvement resources. The company's platform leverages a large consumer database and machine learning to facilitate targeted actions, making it easier for consumers to engage in activities that promote their health and wellbeing. Through its innovative solutions, Welltok aims to incentivize and support users in optimizing their health outcomes.

Tempus Labs, Inc. is a technology company based in Chicago, Illinois, that focuses on advancing precision medicine through the application of artificial intelligence in healthcare. Founded in 2015, Tempus has established one of the world's largest libraries of clinical and molecular data, enabling physicians to make real-time, data-driven decisions for personalized patient care. The company offers a range of services, including genomic sequencing, clinical data restructuring, image recognition, and biological modeling. By collecting, cleansing, and analyzing data, Tempus facilitates the discovery, development, and delivery of optimized therapeutic options for patients. Its innovative platform aims to enhance the accuracy and personalization of laboratory tests, ultimately benefiting patients through insights gained from previous cases.

Radiology Partners is a healthcare service company that specializes in providing comprehensive radiology services to hospitals, clinics, and imaging centers across multiple states. The company focuses on enhancing the practice of radiology by bringing together radiologists, clinical leaders, and advanced radiology services. It offers both diagnostic and interventional radiology solutions, aiming to meet the needs of various healthcare facilities while ensuring high-quality care for patients and support for referring physicians. By prioritizing collaboration and clinical excellence, Radiology Partners strives to exceed client expectations and make a significant impact in the field of radiology.

Woebot Health is a digital mental healthcare provider that focuses on delivering personalized support through an innovative platform. This platform integrates advanced artificial intelligence and natural language processing with established therapeutic techniques to create engaging mental health tools. At the core of its offering is Woebot, a relational agent designed to provide continuous, empathic, and personalized care. By leveraging these technologies, Woebot Health enables individuals and businesses to access effective mental health support conveniently and seamlessly, fitting into everyday life and promoting overall well-being.

Liquidia Technologies is a clinical biopharmaceutical company dedicated to developing and commercializing therapeutics that address unmet patient needs, primarily through its proprietary PRINT technology. This particle engineering platform allows for the precise production of uniform drug particles, enhancing the safety and efficacy of various treatments. The company is currently advancing two key product candidates: LIQ861, aimed at treating pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across diverse therapeutic areas and drug types. One of its marketed products is YUTREPIA, an inhalation powder for treating pulmonary arterial hypertension.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing non-opioid and non-addictive therapies aimed at addressing chronic pain. The company's product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, and in Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain associated with inflammatory, neuropathic, and mixed conditions. Other candidates under development include CNTX-6970, for inflammatory pain, and CNTX-2022, a high-concentration topical gel formulation of lidocaine for various types of pain. CNTX-6016 is also in pre-clinical stages focusing on chronic neuropathic pain. Founded in 2013, Centrexion Therapeutics aims to provide safe and effective solutions for patients suffering from chronic pain conditions.

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, specializing in the design and development of hearing aids for individuals with hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, along with online hearing screenings and virtual support services to eliminate the need for in-person visits. The company's innovative approach aims to address common barriers to hearing aid adoption, such as social stigma, accessibility, and cost, thereby enhancing the quality of life for its users. Eargo sells its products directly to consumers through online platforms, positioning itself as a modern alternative to traditional hearing aid solutions.

Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The organization identifies and mitigates the risks associated with compounds that have therapeutic and commercial potential. Through a rigorous process, Cydan generates data to support the development of new therapies and the formation of new companies. Their experienced team leverages strong relationships with academia and patient advocacy groups, along with deep expertise in drug development and a proven track record of successful product commercialization. By guiding therapies through clinical, regulatory, and commercial development, Cydan aims to improve the lives of patients and families affected by rare diseases.

ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

Tempus Labs, Inc. is a technology company based in Chicago, Illinois, that focuses on advancing precision medicine through the application of artificial intelligence in healthcare. Founded in 2015, Tempus has established one of the world's largest libraries of clinical and molecular data, enabling physicians to make real-time, data-driven decisions for personalized patient care. The company offers a range of services, including genomic sequencing, clinical data restructuring, image recognition, and biological modeling. By collecting, cleansing, and analyzing data, Tempus facilitates the discovery, development, and delivery of optimized therapeutic options for patients. Its innovative platform aims to enhance the accuracy and personalization of laboratory tests, ultimately benefiting patients through insights gained from previous cases.